Prognosis
Novavax Tumbles After Warning of ‘Substantial Doubt’ Over Future
- Company fell short of estimates in its fourth-quarter results
- Novavax struggled to develop and sell its Covid-19 vaccine
This article is for subscribers only.
Novavax Inc. said there’s substantial doubt about its ability to stay in business through next year, the latest warning from the company after it struggled to develop and sell a Covid-19 vaccine. The stock plunged in extended trading.
“Significant uncertainty” surrounds 2023 revenue even though there should be enough money to fund operations, the Gaithersburg, Maryland-based drugmaker said in a statement Tuesday. The warning came as the company reported a fourth-quarter loss almost twice as wide as analysts had estimated.